Management tracks: BioMarin's first chief scientific strategy officer; plus Ascletis, Grail, Aerie and more

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) promoted Lon Cardon to the newly created role of chief scientific strategy officer from CSO. Prior to BioMarin, Cardon was SVP of alternative discovery and development and head of target sciences at

Read the full 364 word article

User Sign In